News

Article about 2A Pharma in the Danish pharma/biotech media MedWatch (behind paywall): Danish: https://medwatch.dk/secure/Medicinal___Biotek/article11272123.ece English: https://medwatch.dk/secure/Top_picks_in_english/article11274345.ece

Press Release Malmö, Sweden - 13 March 20192A Pharma, the Swedish/Danish vaccine company today announced that, approximately 27 months after the company was founded, its novel, broad coverage, HPV L2 vaccine candidate formulated without adjuvant, has progressed into a phase 1 clinical trial and dosing of the sentinel group is completed. The...

2A Pharma has received approval from the UK Medicines and Healthcare products Regulatory Authority and from the local Ethics Committee to proceed with a first-in-human study of 2AP01, which is being developed as broad coverage prophylactic HPV vaccine formulated without adjuvants. 2A Pharma expects that screening of volunteers will commence...

We are extremely pleased to announce that 2A Pharma in collaboration with partners from The Danish Technological Institute and Danish biotech company DNA Sense have been granted EUR 653,000 Eurostars funding for 2AP07 , a project to develop a therapeutic head and neck cancer vaccine. Head and neck cancers represent the sixth most...

2A Pharma is very happy to announce that we will present at BIO Europe 2018. Please join us on Tuesday, 6 November 2018 at 4.30pm in room B3 (level 0).

2A Pharma is very pleased to announce that it has raised SEK 20 million (USD 2.2M)  from existing and new investors. This funding augments the previously raised SEK 27 million (USD 3M) and will enable 2A Pharma to drive its leading vaccine candidate, 2AP01, a broad coverage prophylactic HPV vaccine...

2A Pharma is overwhelmed by the positive responses we received from potential partners and collaborators at BIO-Europe Spring 2018. The conference was a resounding success from our perspective and we are looking forward to continuing the many exciting conversations that were started.

The following article was published in Danish pharma industry publication MedWatch on 16 January 2017. Click here to read the article (paywall).